Lewis C. Cantley

Lewis C. Cantley

Lewis is Professor at the Dana Farber Cancer institute. He is a cell biologist and biochemist who has made groundbreaking discoveries in the area of cancer metabolism. Among his most notable contributions is the discovery and study of the enzyme PI-3 kinase, which is important in diseases like cancer and diabetes. He was previously the Meyer Director and Professor of Cancer Biology at the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine in New York City. He has also held positions as Professor at the Departments of Systems Biology and Medicine at Harvard Medical School and Director of Cancer Research at Beth Israel Deaconess Medical Center in Boston. Prof Cantley is also co-founder of several biotech companies focused on oncology, including Agios Pharmaceuticals, Petra Pharma and Volastra Therapeutics. In 2016, he was elected Chairman of the Board of the Hope Funds for Cancer Research and has over the years received several scientific awards for his research.